Who Should Consider GLP-1 Drugs And Who Shouldn't Good Candidates BMI 30+ (obese) The primary indication for all weight-management GLP-1s BMI 27+ with a weight-related condition (diabetes, high blood pressure, sleep apnea, PCOS, fatty liver) Failed sustained weight loss through diet and exercise alone for 6+ months Pre-diabetic GLP-1s can prevent progression to Type 2 diabetes Cardiovascular risk Semaglutide specifically has proven heart protection Not Appropriate For Cosmetic weight loss of a few kilograms These are serious medications, not diet pills History of medullary thyroid cancer or MEN2 syndrome Absolute contraindication History of pancreatitis Relative contraindication
If you still choose to use compounded tirzepatide, ask your healthcare provider if they have a trusted, preferred pharmacy they regularly use
Take the next step with personalized glutathione-focused care at Natures Healers
Novo Nordisks semaglutide (Ozempic for diabetes, Wegovy for obesity) and Eli Lillys dual-agonist tirzepatide (Mounjaro, a related drug that also activates the GIP hormone receptor) have become blockbusters , propelling their companies to record-high market valuations ( [15] ) ( [16] )
10.1016/j.aca.2012.04.016 Anal Chim Acta
Dosage Strengths and Titration When starting your treatment, your clinical team will guide you through a gradual dose-escalation programme
